DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3033% below fair value
$79.32−0.87 (-1.08%)
Close on Nov 20, 2026Market cap $29.58BP/E 31.2Yield –
DexCom gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
DexCom's gross profit for the twelve months ending Sep 30, 2026 was $3.24B, up 21.5% year over year. For fiscal 2025 it was $2.80B, up 14.9% from the year before. Over ten years it grew 26.0% a year on average. The highest annual figure on record is $2.80B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80B | +14.9% |
| FY2024 | Dec 31, 2024 | $2.44B | +6.5% |
| FY2023 | Dec 31, 2023 | $2.29B | +21.5% |
| FY2022 | Dec 31, 2022 | $1.88B | +12.1% |
| FY2021 | Dec 31, 2021 | $1.68B | +31.3% |
| FY2020 | Dec 31, 2020 | $1.28B | +37.4% |
| FY2019 | Dec 31, 2019 | $931.50M | +40.3% |
| FY2018 | Dec 31, 2018 | $663.90M | +34.9% |
| FY2017 | Dec 31, 2017 | $492.10M | +30.0% |
| FY2016 | Dec 31, 2016 | $378.40M | +35.9% |
| FY2015 | Dec 31, 2015 | $278.40M | +57.9% |
| FY2014 | Dec 31, 2014 | $176.30M | +76.1% |
| FY2013 | Dec 31, 2013 | $100.10M | +114.8% |
| FY2012 | Dec 31, 2012 | $46.60M | +29.8% |
| FY2011 | Dec 31, 2011 | $35.90M | +95.1% |
| FY2010 | Dec 31, 2010 | $18.40M | +402.6% |
| FY2009 | Dec 31, 2009 | $3.66M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $864.40M | +18.2% |
| Q2 FY2026 | Jun 30, 2026 | $830.00M | +20.5% |
| Q1 FY2026 | Mar 31, 2026 | $750.30M | +27.4% |
| Q4 FY2025 | Dec 31, 2025 | $792.70M | +20.9% |
| Q3 FY2025 | Sep 30, 2025 | $731.40M | +23.2% |
| Q2 FY2025 | Jun 30, 2025 | $688.80M | +9.9% |
| Q1 FY2025 | Mar 31, 2025 | $589.00M | +4.8% |
| Q4 FY2024 | Dec 31, 2024 | $655.80M | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $593.80M | -4.7% |
| Q2 FY2024 | Jun 30, 2024 | $626.70M | +14.7% |
| Q1 FY2024 | Mar 31, 2024 | $561.90M | +21.5% |
| Q4 FY2023 | Dec 31, 2023 | $656.60M | +21.3% |
| Q3 FY2023 | Sep 30, 2023 | $623.30M | +26.1% |
| Q2 FY2023 | Jun 30, 2023 | $546.40M | +21.6% |
| Q1 FY2023 | Mar 31, 2023 | $462.60M | +16.2% |
| Q4 FY2022 | Dec 31, 2022 | $541.30M | +14.5% |
| Q3 FY2022 | Sep 30, 2022 | $494.20M | +10.6% |
| Q2 FY2022 | Jun 30, 2022 | $449.50M | +7.8% |
| Q1 FY2022 | Mar 31, 2022 | $398.10M | +15.8% |
| Q4 FY2021 | Dec 31, 2021 | $472.60M | +18.4% |
| Q3 FY2021 | Sep 30, 2021 | $446.90M | +31.3% |
| Q2 FY2021 | Jun 30, 2021 | $417.10M | +46.8% |
| Q1 FY2021 | Mar 31, 2021 | $343.90M | +34.1% |
| Q4 FY2020 | Dec 31, 2020 | $399.10M | +29.0% |
| Q3 FY2020 | Sep 30, 2020 | $340.40M | +37.9% |
| Q2 FY2020 | Jun 30, 2020 | $284.10M | +37.6% |
| Q1 FY2020 | Mar 31, 2020 | $256.50M | +52.0% |
| Q4 FY2019 | Dec 31, 2019 | $309.30M | +38.8% |
| Q3 FY2019 | Sep 30, 2019 | $246.90M | +46.4% |
| Q2 FY2019 | Jun 30, 2019 | $206.50M | +34.4% |
| Q1 FY2019 | Mar 31, 2019 | $168.80M | +42.0% |
| Q4 FY2018 | Dec 31, 2018 | $222.80M | +45.1% |
| Q3 FY2018 | Sep 30, 2018 | $168.60M | +32.8% |
| Q2 FY2018 | Jun 30, 2018 | $153.60M | +30.7% |
| Q1 FY2018 | Mar 31, 2018 | $118.90M | +26.4% |
| Q4 FY2017 | Dec 31, 2017 | $153.50M | +31.5% |
| Q3 FY2017 | Sep 30, 2017 | $127.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $117.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $94.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $116.70M | – |
See a number that looks wrong?